RXRX (Recursion Pharmaceuticals, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RXRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Ben R Taylor | Chief Financial Officer | F | — | — |
| 2026-08-18 | Najat Khan | CEO and President | F | — | — |
| 2026-08-18 | David Hallett | Chief Scientific Officer | F | — | — |
| 2026-08-06 | Blake Borgeson | Director | Sell | — | — |
| 2026-08-06 | Blake Borgeson | Director | Sell | — | — |
| 2026-07-09 | Blake Borgeson | Director | Sell | — | — |
| 2026-07-02 | Zavain Dar | Director | A | — | — |
| 2026-07-02 | Dean Y Li | Director | A | — | — |
| 2026-06-22 | Elaine D Sun | Director | A | — | — |
| 2026-06-22 | ROBERT HERSHBERG | Director | A | — | — |
| 2026-06-22 | Franziska Michor | Director | A | — | — |
| 2026-06-22 | Dean Y Li | Director | A | — | — |
| 2026-06-22 | Blake Borgeson | Director | A | — | — |
| 2026-06-22 | Zavain Dar | Director | A | — | — |
| 2026-06-22 | Namandje Bumpus | Director | MIXED | — | — |
| 2026-06-17 | Ben R Taylor | Chief Financial Officer | F | — | — |
| 2026-06-05 | Najat Khan | CEO and President | Sell | — | — |
| 2026-06-05 | Christopher Gibson | Director | MIXED | — | — |
| 2026-06-04 | Blake Borgeson | Director | Sell | — | — |
| 2026-06-04 | Namandje Bumpus | Director | Sell | — | — |
| 2026-05-27 | Christopher Gibson | Director | MIXED | — | — |
| 2026-05-19 | Ben R Taylor | Chief Financial Officer | F | — | — |
| 2026-05-19 | Najat Khan | CEO and President | F | — | — |
| 2026-05-19 | David Hallett | Chief Scientific Officer | F | — | — |
| 2026-05-19 | Christopher Gibson | Director | F | — | — |
| 2026-05-08 | Christopher Gibson | Director | MIXED | — | — |
| 2026-05-07 | Blake Borgeson | Director | Sell | — | — |
| 2026-04-24 | Christopher Gibson | Director | MIXED | — | — |
| 2026-04-08 | Blake Borgeson | Director | Sell | — | — |
| 2026-04-08 | Ben R Taylor | Chief Financial Officer | F | — | — |
| 2026-04-08 | Christopher Gibson | Director | MIXED | — | — |
| 2026-04-02 | Zavain Dar | Director | A | — | — |
| 2026-04-02 | Dean Y Li | Director | A | — | — |
| 2026-03-25 | Christopher Gibson | Director | MIXED | — | — |
| 2026-03-18 | Ben R Taylor | Chief Financial Officer | MIXED | — | — |
| 2026-03-11 | Najat Khan | CEO and President | Sell | — | — |
| 2026-03-11 | Christopher Gibson | Director | MIXED | — | — |
| 2026-03-04 | Blake Borgeson | Director | Sell | — | — |
| 2026-02-19 | Ben R Taylor | Chief Financial Officer | MIXED | — | — |
| 2026-02-19 | Najat Khan | CEO and President | F | — | — |
| 2026-02-19 | David Hallett | Chief Scientific Officer | F | — | — |
| 2026-02-19 | Christopher Gibson | Director | MIXED | — | — |
| 2026-02-10 | Ben R Taylor | Chief Financial Officer | MIXED | — | — |
| 2026-02-10 | Najat Khan | CEO and President | MIXED | — | — |
| 2026-02-10 | David Hallett | Chief Scientific Officer | MIXED | — | — |
| 2026-02-06 | Blake Borgeson | Director | Sell | — | — |
| 2026-02-06 | Christopher Gibson | Director | MIXED | — | — |
| 2026-01-22 | Christopher Gibson | Director | MIXED | — | — |
| 2026-01-08 | Blake Borgeson | Director | Sell | — | — |
| 2026-01-07 | Christopher Gibson | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | — | 13,021,519 | — |
| — | 10%+ Owner | 12,985,927 | — |
| — | 10%+ Owner | 12,919,105 | — |
| — | Director | 6,188,287 | — |
| — | 10%+ Owner | 3,951,141 | — |
| — | Director | 3,736,341 | — |
| — | Director | 2,895,377 | — |
| — | CEO and President | 2,095,298 | — |
| — | Chief Financial Officer | 1,487,694 | — |
| — | Chief Financial Officer | 1,076,858 | — |
| — | Chief Scientific Officer | 1,043,837 | — |
| — | Director | 901,610 | — |
| — | President and COO | 506,852 | — |
| — | Director | 240,764 | — |
| — | Chief Medical Officer | 225,429 | — |
| — | Director | 215,477 | — |
| — | Director | 162,156 | — |
| — | Chief Business Officer | 154,748 | — |
| — | Director | 135,981 | — |
| — | Director | 131,595 | — |
| — | Chief Medical Officer | 121,110 | — |
| — | 10%+ Owner | 100,000 | — |
| — | Director | 71,254 | — |
| — | Director | 60,078 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RXRX quote page; the site-wide leaderboard is on the insider transactions hub.